RxDoctor Payments Data
★ My doctorsLook up a doctor →

Alejandro Plan

Endocrinology, Diabetes & Metabolism · Longview, TXNPI 1477660041

Payments from drug & device makers

$2,192in general payments, 2019–2025

Across 136 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$577
  • Lilly USA, LLC$430
  • Medtronic$189
  • AstraZeneca$183
  • Novo Nordisk$137
  • Merck$134
  • plus $543 from 11 others

What the payments were for

  • Food & beverage$2,192100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC41$577
Lilly USA, LLC25$430
Medtronic(2 entities)8$189
AstraZeneca12$183
Novo Nordisk8$137
Merck8$134
Insulet Corporation8$125
Dexcom, Inc.5$69
Boehringer Ingelheim4$61
Corcept Therapeutics4$57
Johnson & Johnson3$51
Abbott3$51
Xeris Pharmaceuticals, Inc.2$35
Amgen1$29
IBSA Pharma Inc.2$26
Bayer1$20
Sun Pharmaceutical Industries Inc.1$19

How this compares

$2,192 in reported general payments places this provider in the 40th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Other endocrinology, diabetes & metabolism in Longview

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →